Prelabeling of chimeric monoclonal antibody L6 with90yttrium- and 111indium-1,4,7,10-tetraazacyclododecane-N,N′,N″, N‴-tetraacetic acid (DOTA) chelates for radioimmunodiagnosis and therapy

Min Li, Claude F. Meares, Qansy Salako, David L. Kukis, Gao Ren Zhong, Laird Miers, Sally J. DeNardo

Research output: Contribution to journalArticle

19 Scopus citations

Abstract

90Y and 111In have been attached to chimeric monoclonal antibody L6 with a bifunctional chelating agent (DOTA-peptide isothiocyanate). The bifunctional chelating agent was prelabeled with either radiometal and then conjugated to the antibody. Studies in human patients showed excellent 111In single-photon emission computed tomography images of breast cancer lesions 24 h after injection.

Original languageEnglish (US)
JournalCancer Research
Volume55
Issue number23 SUPPL.
StatePublished - 1995

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Prelabeling of chimeric monoclonal antibody L6 with<sup>90</sup>yttrium- and <sup>111</sup>indium-1,4,7,10-tetraazacyclododecane-N,N′,N″, N‴-tetraacetic acid (DOTA) chelates for radioimmunodiagnosis and therapy'. Together they form a unique fingerprint.

  • Cite this